Enlivex Therapeutics Company Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis.

The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.

Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

Country	Israel
Industry	Biotechnology
Sector	Healthcare
CEO	Oren Hershkovitz

Contact Details

Address: 14 Einstein Street Ness Ziona, 7403618 Israel
Phone	972 2 670 8072
Website	enlivex.com

Stock Details

Ticker Symbol	ENLV
Exchange	Tel Aviv Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	IL0011319527
SIC Code	2836

Key Executives

Name	Position
Dr. Oren Hershkovitz Ph.D.	Chief Executive Officer
Shai Novik M.B.A.	Executive Chairman
Shachar Shlosberger CPA	Chief Financial Officer
Veronique Amor-Baroukh	Senior Director of Operations
Sigal Arad	Director of Human Resources